Synaptogenix Inc

NASDAQ:SNPXUnited States

Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.

Contact Information

Headquarters

1185 AVENUE OF THE AMERICAS, 3RD FLOORNEW YORK, NY, United States 10036

Phone

973-242-0005

Fax

302-655-5049

Executives

Independent Chairman of the Board

Joshua Silverman

President, Chief Scientific Officer, Director

Daniel Alkon

Chief Executive Officer, Director

Alan Tuchman

Independent Non-Executive Vice Chairman of the Board

William Singer

Chief Financial Officer, Executive Vice President, Treasurer, Secretary

Robert Weinstein